A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation
Status:
Recruiting
Trial end date:
2033-01-15
Target enrollment:
Participant gender:
Summary
This research is being done to evaluate Glofitamab by itself or in combination with
Polatuzumab Vedotin or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia
(CLL) that has transformed into Richter's Transformation (RT).
The names of the study drugs involved in this research study are:
- Glofitamab (a T-cell bispecific humanized monoclonal antibody)
- Obinutuzumab (a humanized glycoengineered type II anti-CD20 monoclonal antibody)
- Polatuzumab vedotin (an antibody-drug conjugate)
- Atezolizumab (a humanized immunoglobulin monoclonal antibody)
- Tocilizumab (a recombinant, humanized, anti-human monoclonal antibody)